VA
FULC icon

VR Adviser’s Fulcrum Therapeutics FULC Stock Holding History

VR Adviser’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,307,094
Closed -$3.73M – 33
2023
Q1 		$3.73M Buy
1,307,094
+859,768
+192% +$7.7M 0.73% 21
2022
Q4 		$3.26M Sell
447,326
-752,674
-63% -$4.91M 0.55% 23
2022
Q3 		$9.71M Buy
+1,200,000
New +$8.59M 1.5% 18

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser's FULC Position: Q2 2023 in Review

VR Adviser sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 1,307,094 shares — an estimated $3.73M sold.

VR Adviser first reported a position in FULC in Q3 2022 and held it in 3 quarters. The position peaked at $9.71M in Q3 2022. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • VR Adviser reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • VR Adviser sold 1,307,094 Fulcrum Therapeutics shares in Q2 2023, an estimated $3.73M.
  • VR Adviser first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 3 quarters.
  • VR Adviser's Fulcrum Therapeutics position peaked at $9.71M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on VR Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.